These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37783206)

  • 21. Change in Mycophenolate and Tacrolimus Exposure by Transplant Vintage and Race.
    Soliman KM; Posadas Salas AC; Taber DJ
    Exp Clin Transplant; 2019 Dec; 17(6):707-713. PubMed ID: 30570456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pediatric Lung Transplant Outcomes Based on Immunosuppressive Regimen at Discharge: Retrospective Cohort Study Using Real-World Evidence From the US Scientific Registry of Transplant Recipients.
    Erdman J; Wolfram J; Nimke D; Croy R; Wang X; Weaver T; Schladt D; Fitzsimmons WE
    Transplant Proc; 2023 Sep; 55(7):1692-1705. PubMed ID: 37438193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors affecting kidney-transplant outcome in recipients with lupus nephritis.
    Tang H; Chelamcharla M; Baird BC; Shihab FS; Koford JK; Goldfarb-Rumyantzev AS
    Clin Transplant; 2008; 22(3):263-72. PubMed ID: 18482047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients.
    de Boer SE; Sanders JSF; Bemelman FJ; Betjes MGH; Burgerhof JGM; Hilbrands L; Kuypers D; van Munster BC; Nurmohamed SA; de Vries APJ; van Zuilen AD; Hesselink DA; Berger SP
    BMC Nephrol; 2021 Jun; 22(1):208. PubMed ID: 34078323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of mismatches for HLA-DR with incidence of posttransplant hip fracture in kidney transplant recipients.
    Opelz G; Döhler B
    Transplantation; 2011 Jan; 91(1):65-9. PubMed ID: 21452411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety profile comparing azathioprine and mycophenolate in kidney transplant recipients receiving tacrolimus and corticosteroids.
    Cristelli MP; Tedesco-Silva H; Medina-Pestana JO; Franco MF
    Transpl Infect Dis; 2013 Aug; 15(4):369-78. PubMed ID: 23701592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined introduction of anti-IL2 receptor antibodies, mycophenolic acid and tacrolimus: effect on malignancies after renal transplantation in a single-centre retrospective cohort study.
    Braconnier P; Del Marmol V; Broeders N; Kianda M; Massart A; Lemy A; Ghisdal L; Le Moine A; Madhoun P; Racapé J; Abramowicz D; Wissing KM
    Nephrol Dial Transplant; 2012 Jun; 27(6):2547-53. PubMed ID: 22123748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quadruple immunosuppression with basiliximab, tacrolimus, mycophenolate mofetil and prednisone is safe and effective for renal transplantation.
    Miura M; Harada H; Fukuzawa N; Iwami D; Taniguchi A; Seki T; Togashi M; Ogawa Y; Satoh H; Hirano T
    Clin Transplant; 2005; 19 Suppl 14():54-8. PubMed ID: 15955170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Side effects of mycophenolate mofetil versus azathioprine in iranian renal transplant recipients (single-center experience).
    Hakemi M; Shahebrahimi K; Ganji MR; Najafi I; Broumand B
    Transplant Proc; 2002 Sep; 34(6):2091-2. PubMed ID: 12270326
    [No Abstract]   [Full Text] [Related]  

  • 30. Combination therapy with diltiazem plus CsA/MMF/Pred or CsA/Aza/Pred triple immunosuppressive regimens for use in clinical kidney transplantation in Northwestern China.
    Song Y; Xue W; Tian P; Ding X; Pan X; Yan H; Hou J; Feng X; Xiang H; Tian X; Qin G; Fan X
    Eur J Clin Pharmacol; 2011 Jun; 67(6):553-62. PubMed ID: 21279337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
    Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
    Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lung Transplant Outcomes in Adults in the United States: Retrospective Cohort Study Using Real-world Evidence from the SRTR.
    Erdman J; Wolfram J; Nimke D; Croy R; Wang X; Weaver T; Schladt D; Fitzsimmons WE
    Transplantation; 2022 Jun; 106(6):1233-1242. PubMed ID: 34974456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression.
    Luan FL; Steffick DE; Ojo AO
    Transplantation; 2011 Feb; 91(3):334-41. PubMed ID: 21242885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial.
    Abramowicz D; Vanrenterghem Y; Squifflet JP; Kuypers D; Mourad M; Meurisse M; Wissing M
    Clin Transplant; 2005 Aug; 19(4):475-82. PubMed ID: 16008591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients.
    Machnicki G; Ricci JF; Brennan DC; Schnitzler MA
    Pharmacoeconomics; 2008; 26(11):951-67. PubMed ID: 18850764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Mycophenolate Mofetil Dose Reduction on Allograft Outcomes in Kidney Transplant Recipients on Tacrolimus-Based Regimens: A Systematic Review.
    Su VCh; Greanya ED; Ensom MH
    Ann Pharmacother; 2011 Feb; 45(2):248-57. PubMed ID: 21304036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initial mycophenolate dose in tacrolimus treated renal transplant recipients, a cohort study comparing leukopaenia, rejection and long-term graft function.
    Dave V; Polkinghorne KR; Leong KG; Kanellis J; Mulley WR
    Sci Rep; 2020 Nov; 10(1):19379. PubMed ID: 33168923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal cell cancer after kidney transplantation.
    Kleine-Döpke D; Oelke M; Schwarz A; Schwager Y; Lehner F; Klempnauer J; Schrem H
    Langenbecks Arch Surg; 2018 Aug; 403(5):631-641. PubMed ID: 30003323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA): A pragmatic randomized trial.
    Ruggenenti P; Cravedi P; Gotti E; Plati A; Marasà M; Sandrini S; Bossini N; Citterio F; Minetti E; Montanaro D; Sabadini E; Tardanico R; Martinetti D; Gaspari F; Villa A; Perna A; Peraro F; Remuzzi G
    PLoS Med; 2021 Jun; 18(6):e1003668. PubMed ID: 34166370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tuberculosis in renal transplant recipients on various immunosuppressive regimens.
    Atasever A; Bacakoglu F; Toz H; Basoglu OK; Duman S; Basak K; Guzelant A; Sayiner A
    Nephrol Dial Transplant; 2005 Apr; 20(4):797-802. PubMed ID: 15703207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.